Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note issued to investors on Wednesday,Benzinga reports. Chardan Capital currently has a $212.00 target price on the stock.

A number of other equities analysts also recently issued reports on KRYS. Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Finally, Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average target price of $206.67.

Krystal Biotech Trading Down 7.3 %

Shares of NASDAQ:KRYS opened at $156.64 on Wednesday. The company has a market capitalization of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The business has a 50 day moving average of $180.70 and a two-hundred day moving average of $185.17.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.67) earnings per share. Equities research analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. EFG Asset Management North America Corp. raised its stake in Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares during the period. Nisa Investment Advisors LLC grew its position in Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after acquiring an additional 94 shares during the period. Arizona State Retirement System increased its stake in Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares during the last quarter. Fiera Capital Corp raised its position in Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after purchasing an additional 130 shares during the period. Finally, KBC Group NV grew its holdings in shares of Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).